UY39866A - Sales y formas en estado sólido de un compuesto inhibidor de kif18a - Google Patents
Sales y formas en estado sólido de un compuesto inhibidor de kif18aInfo
- Publication number
- UY39866A UY39866A UY0001039866A UY39866A UY39866A UY 39866 A UY39866 A UY 39866A UY 0001039866 A UY0001039866 A UY 0001039866A UY 39866 A UY39866 A UY 39866A UY 39866 A UY39866 A UY 39866A
- Authority
- UY
- Uruguay
- Prior art keywords
- kif18a
- salts
- solid state
- inhibitor compound
- state forms
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 101001091231 Homo sapiens Kinesin-like protein KIF18A Proteins 0.000 title 1
- 229940126262 KIF18A Drugs 0.000 title 1
- 102100034895 Kinesin-like protein KIF18A Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- KBDGEJDIHZDPHN-UHFFFAOYSA-N 2-(6-azaspiro[2.5]octan-6-yl)-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]-4-(2-hydroxyethylsulfonylamino)benzamide Chemical compound FC1(CCN(CC1)C1=NC(=CC(=N1)NC(C1=C(C=C(C=C1)NS(=O)(=O)CCO)N1CCC2(CC2)CC1)=O)C)F KBDGEJDIHZDPHN-UHFFFAOYSA-N 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- 102000010638 Kinesin Human genes 0.000 abstract 1
- 108010063296 Kinesin Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En el presente documento, se divulga una sal, una forma anhidra cristalina, un hidrato, un solvato o un cocristal de un compuesto de base libre 2-(6-azaespiro[2.5]octan-6-il)-N-[2-(4,4-difluoropiperidin-1-il)-6-metilpirimidin-4-il]-4-[(2-hidroxietanosulfonil)amino]benzamida (Compuesto A); un método de preparación, composiciones farmacéuticas y un método de tratamiento de una enfermedad mediada por la inhibición de un miembro 18A de la familia de la proteína motora cinesina (KIF18A), en donde dicha enfermedad es una enfermedad neoplásica, incluyendo un cáncer o un tumor.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163224208P | 2021-07-21 | 2021-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39866A true UY39866A (es) | 2023-01-31 |
Family
ID=83148993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039866A UY39866A (es) | 2021-07-21 | 2022-07-21 | Sales y formas en estado sólido de un compuesto inhibidor de kif18a |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4373818A1 (es) |
| KR (1) | KR20240051338A (es) |
| CN (1) | CN117940416A (es) |
| AR (1) | AR126537A1 (es) |
| AU (1) | AU2022313961A1 (es) |
| CA (1) | CA3226614A1 (es) |
| IL (1) | IL310234A (es) |
| TW (1) | TW202321213A (es) |
| UY (1) | UY39866A (es) |
| WO (1) | WO2023004075A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202345802A (zh) * | 2022-04-15 | 2023-12-01 | 大陸商武漢人福創新藥物研發中心有限公司 | Kif18a抑制劑及其用途 |
| CN116535400A (zh) * | 2023-04-26 | 2023-08-04 | 上海湃隆生物科技有限公司 | 氮杂螺环化合物及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8576985B2 (en) | 2009-09-01 | 2013-11-05 | Aptuit (West Lafayette) Llc | Methods for indexing solid forms of compounds |
| US11236069B2 (en) | 2018-12-20 | 2022-02-01 | Amgen Inc. | KIF18A inhibitors |
| JP2023521802A (ja) * | 2020-04-14 | 2023-05-25 | アムジエン・インコーポレーテツド | 新生物疾患の処置のためのｋｉｆ１８ａ阻害剤 |
-
2022
- 2022-07-18 TW TW111126873A patent/TW202321213A/zh unknown
- 2022-07-21 KR KR1020247005985A patent/KR20240051338A/ko unknown
- 2022-07-21 AU AU2022313961A patent/AU2022313961A1/en active Pending
- 2022-07-21 UY UY0001039866A patent/UY39866A/es unknown
- 2022-07-21 CA CA3226614A patent/CA3226614A1/en active Pending
- 2022-07-21 WO PCT/US2022/037928 patent/WO2023004075A1/en active Application Filing
- 2022-07-21 AR ARP220101934A patent/AR126537A1/es unknown
- 2022-07-21 IL IL310234A patent/IL310234A/en unknown
- 2022-07-21 EP EP22761662.0A patent/EP4373818A1/en active Pending
- 2022-07-21 CN CN202280060739.4A patent/CN117940416A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240051338A (ko) | 2024-04-19 |
| CA3226614A1 (en) | 2023-01-26 |
| AU2022313961A1 (en) | 2024-02-08 |
| IL310234A (en) | 2024-03-01 |
| AR126537A1 (es) | 2023-10-18 |
| TW202321213A (zh) | 2023-06-01 |
| CN117940416A (zh) | 2024-04-26 |
| WO2023004075A1 (en) | 2023-01-26 |
| EP4373818A1 (en) | 2024-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39866A (es) | Sales y formas en estado sólido de un compuesto inhibidor de kif18a | |
| CA2300051A1 (en) | Amide derivatives for the treatment of diseases mediated by cytokines | |
| PE20231438A1 (es) | Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo | |
| MX2022011365A (es) | Derivados de biarilo como inhibidores de la interaccion proteina-proteina de yap/taz-tead. | |
| AR057874A1 (es) | Aminopirimidinas utiles como inhibidores de quinasa | |
| AR064256A1 (es) | Sales y formas de cristal del 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-dihidro-imidazo-[4,5-c] -quinolin-1-il)-fenil] -propionitrilo | |
| CA2476065A1 (en) | Inhibitors of histone deacetylase | |
| AR042941A1 (es) | Derivados de tiazol, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos inhibidores de la proteina-1 de adhesion vascular (vap-1) | |
| BR0313968A (pt) | Derivados de heteroaril nitrila | |
| AR066972A1 (es) | Derivados azapeptidicos | |
| CA2526989A1 (en) | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | |
| CY1109085T1 (el) | Νεα αλατα | |
| PE20220962A1 (es) | Formas de sales cristalinas de un inhibidor de cinasas | |
| MX2022006333A (es) | Compuesto triheterociclico como inhibidor de jak y uso del mismo. | |
| AR128500A1 (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| CL2022003008A1 (es) | Procesos para la preparación de un inhibidor de cinasa | |
| RU2008149936A (ru) | (2r)-2-[(4-сульфонил)аминофенил]пропанамиды и содержащие их фармацевтические композиции | |
| ECSP23054131A (es) | Cocristal de un inhibidor de cdk | |
| MX2010010561A (es) | Derivados tiazol de benzofenona utiles para inhibir la formacion del microtúbulo, y método para producir los mismos. | |
| AR045728A1 (es) | Composiciones de un inhibidor de catepsina k y un bifosfonato en el tratamiento de metastasis osea, crecimiento de tumor y perdida osea inducida por tumor | |
| HK1057886A1 (en) | Aryl sulfonamides as serotonin antagonist for the treatment of obesity | |
| US8518885B2 (en) | Heterocyclic peptide ketoamides | |
| RU2005138049A (ru) | Новые биоизостеры актинонина | |
| CA2434829A1 (en) | New benzoylguanidine salt | |
| MX2022013692A (es) | Compuesto que tiene actividad inhibidora de desmetilasa 5 (kdm5) y uso farmaceutico del mismo. |